Professor Mark Marzinke presenting at CROI 2023. Photo by Roger Pebody.When it comes to HIV in heterosexuals, women are often at a disadvantage to men. Globally, they are more likely to have HIV, and to acquire it at a younger age; biologically and socially they are more vulnerable; and biomedical prevention studies have often produced poorer results.
A study presented at CROI 2023 provided somewhat better news. This analysis of the HPTN 084 study – which found remarkable efficacy for injections of cabotegravir as PrEP in cisgender women – found that drug levels persist long enough in women to mean that an injection every three months, as opposed to every two months as in HPTN 084, might still be effective.
Read the full story at Aidsmap.
Source : Aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.